|
|
|
|
|
|
Why Choose City of Hope?
Pioneers in advancing care for all hematologic cancers and other blood-related disorders, City of Hope's Department of Hematology and Hematopoietic Cell Transplantation is a leader in setting standards for treatment worldwide and in improving long-term outcomes for both children and adults.
City of Hope combines important research discoveries with superior clinical techniques to diagnose, evaluate and provide the most advanced treatments for
- City of Hope leads the field of hematopoietic cell transplantation (HCT) as one of the world’s largest and most successful transplant centers.
- HCT is also useful in treating other cancers such as breast cancer and ovarian cancer, as well as noncancerous conditions such as inherited disorders of the bone marrow and autoimmune diseases such as scleroderma.
- Our renowned multidisciplinary team is comprised of nationally recognized experts in the care of patients with these disorders.
|
|
|
City of Hope has performed more than 11,000 transplants for patients from virtually every state as well as from numerous countries. HCT and PBSCT patients at City of Hope have ranged in age from less than one year old to 79. City of Hope’s HCT program is one of America’s largest, dedicated solely to the traditional and newer uses of this procedure. Allogeneic HCT is used primarily for the treatment of diseases that invade the bone marrow, such as acute and chronic leukemia, myelodysplasia and myeloma. Autologous HCT is used primarily for the treatment of diseases such as lymphoma, Hodgkins disease, acute myelogenous leukemia, myeloma, breast cancer and testicular cancer. This process was first used in the early 1970s. City of Hope’s HCT Program began in 1976. City of Hope began performing PBSCTs in 1988.
Patients receive one of two types of stem cell-based transplants: autologous, in which a patient donates and receives back his/her own stem cells; or allogeneic, in which bone marrow-derived stem cells come from a related or unrelated donor whose human leukocyte antigens (HLA), are genetically matched with those of a patient. Peripheral blood stem cells are generally used in autologous transplantations, while either marrow or peripheral blood stem cells are used in allogeneic transplantations. |
|
|
|
City of Hope was one of the first medical centers in the nation to perform a successful bone marrow transplant (BMT) for leukemia, in 1976.
Today, City of Hope leads the field of hematopoietic cell transplantation (HCT) as one of the world’s largest and most successful transplant centers.
We combine important research discoveries with superior clinical techniques to provide the most advanced treatments for leukemia, lymphoma, multiple myeloma, myelodysplasia and other blood disorders. City of Hope physicians are nationally recognized experts in the care of patients with these disorders.
We also provide new options for patients contemplating HCT – options which may make transplants possible for those who might not have previously been considered good transplant candidates.
These strengths have resulted in improved treatment outcomes, with longer disease-free survival, increased cure rates and fewer complications from treatment.
|
|
|
Forms of HCT
BMT, the most familiar form of HCT, involves taking stem cells from donor bone marrow and transplanting them into a patient whose bone marrow is compromised by leukemia, lymphoma, myeloma, myelodysplasia, other cancers, or genetic disorders. The transplanted stem cells can then develop into normal blood cells, and the patient essentially gains a new immune system.
HCT also comprises two newer methods: peripheral blood cell transplantation and cord blood transplantation. Peripheral blood and cord blood (from the umbilical cord) both yield stem cells, which can be transplanted just as bone marrow can.
New Options in Transplants
City of Hope physicians are leaders in performing BMT/HCT transplants, continually refining and perfecting therapeutic techniques based on developing research.
History of Success
City of Hope has a solid history of success in developing novel therapies to treat a wide variety of diseases. Diseases treated with HCT include hematologic cancers such as acute and chronic leukemias, lymphomas, Hodgkin’s disease, as well as myelodysplastic syndromes and myeloproliferative disorders. HCT is also useful in treating other cancers such as breast cancer and ovarian cancer, as well as noncancerous conditions such as inherited disorders of the bone marrow and autoimmune diseases such as scleroderma.
We have designed and tested effective treatment programs for both initial treatment as well as treatment of relapse for patients with these disorders. The many success stories of our patients who have survived decades after their transplants are a resounding testament to City of Hope physicians’ expertise.
|
|
|
|
View full size video >> |
| Stephen J. Forman, M.D., chair of hematology and hematopoietic cell transplantation, shares his views on the essence of care at City of Hope. He highlights the bone marrow transplant program (BMT) and the program's growth over the years. |
|
|
Click on date to add event to your calendar.
|
|
 City of Hope's partnership with the LA Dodgers, includes ThinkCure!, an innovative, community-based non-profit that raises funds to accelerate collaborative research at City of Hope and Childrens Hospital Los Angeles to cure cancers.
Learn more >>
|
|
|
|
|  |
|
| Advanced Search Options |
| News & Publications Search |
 |
|
|
|
|
10,000 9,000 8,000 7,000 6,000 5,000 4,000 3,000 2,000 1,000 11,396 HCTs Performed as of May 25, 2013  |
|
|
